Lisa Astor | Authors


FDA Has Granted Priority Review to Tisotumab Vedotin for Advanced Cervical Cancer

April 10, 2021

The FDA has accepted a biologics license application and granted it a priority review for tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Regorafenib/Nivolumab Proof of Concept Suggested in Third-Line, Refractory HCC

March 28, 2021

Half of all patients with hepatocellular carcinoma treated with the combination of regorafenib and nivolumab following progression on 2 lines of chemotherapy achieved disease control, according to initial results from a phase 2 proof-of-concept trial.

FDA Approves Ide-Cel for Relapsed/Refractory Multiple Myeloma

March 27, 2021

The FDA has approved idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.